CNS Pharmaceuticals, Inc. Net Fee Amt
CNS Pharmaceuticals, Inc. (CNSP) had Net Fee Amt of $6.50 thousand as of 2026-05-15, per its S-3 filed 2026-05-19.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-19
- 2026-05-15: Net Fee Amt $6.50K.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-15 | $6.50K S-3 · filed 2026-05-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |